Maintain compliance with a Direct to Patient via Site drug shipment strategy
Supporting patients enrolled in clinical trials, and improving their participation experience, is a top priority for sponsors.
Developing a drug shipment strategy to introduce enhanced convenience to patients not only supports retention, by reducing a patient’s travel time, costs and number of visits to a clinical site, but delivers added value to sponsors through improved supply chain continuity and end to end temperature controlled compliance.
A Direct to Patient (DtP) via site strategy, where investigational products (IP) are dispatched from a depot to a clinical site before being dispensed by a pharmacist to the patient’s home, can open-up trials to a wider patient population. In doing so, it can accelerate a trial’s total duration, making new medications accessible to patients more quickly.